Medpace Holdings, Inc. $MEDP Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 33.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 177,853 shares of the company’s stock after selling 87,417 shares during the period. JPMorgan Chase & Co.’s holdings in Medpace were worth $91,445,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Quent Capital LLC acquired a new stake in shares of Medpace during the third quarter worth about $25,000. Optiver Holding B.V. acquired a new stake in shares of Medpace in the 3rd quarter valued at about $27,000. Geneos Wealth Management Inc. grew its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Quarry LP acquired a new position in Medpace during the third quarter worth approximately $35,000. Finally, Employees Retirement System of Texas acquired a new position in Medpace during the second quarter worth approximately $36,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Trading Up 0.3%

NASDAQ:MEDP opened at $455.15 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92. The stock’s 50 day simple moving average is $517.88 and its 200-day simple moving average is $539.13. The firm has a market cap of $12.92 billion, a P/E ratio of 29.75, a PEG ratio of 2.17 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same period last year, the company earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on MEDP shares. Royal Bank Of Canada assumed coverage on Medpace in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price objective for the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and decreased their price target for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective on the stock in a research report on Friday, February 13th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Five investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Medpace currently has a consensus rating of “Hold” and an average price target of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.